Pasireotide is under clinical development by Recordati and currently in Phase II for Medullary Thyroid Cancer. According to GlobalData, Phase II drugs for Medullary Thyroid Cancer have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Pasireotide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pasireotide overview
Pasireotide (Signifor, Upelior) is a synthetic polypeptide analogue of somatostatin. It is formulated as injectable solution and powder for suspension for subcutaneous route of administration. Pasireotide is indicated for the treatment of adult patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.
Pasireotide is under development for the treatment of medullary thyroid cancer, papillary thyroid cancer, metastatic liver cancer and follicular thyroid cancer and post bariatric hypoglycemia.
It was also under development for Nelson syndrome, fistula, meningioma, leak, cluster headache, dumping syndrome, hepatocellular carcinoma, hypoglycemia, metastatic hepatocellular carcinoma, abscess and carcinoid tumors including neuroendocrine gastroenteropancreatic tumors. It was also under development for the treatment of unresectable neuroendocrine hepatic metastases
Recordati overview
Recordati, a subsidiary of Fimei SpA, is a pharmaceutical company that researches, develops, manufactures and markets pharmaceuticals. The company offers pharmaceuticals for cardiovascular diseases, central nervous system disorders, dermatology, musculoskeletal disorders and analgesia, and urology diseases. It also offers cosmetics, dietary supplements, pregnancy test products, over-the-counter (OTC) and non-prescription pharmaceuticals, anti-infectives, and others. It manufactures pharmaceutical chemicals such as active pharmaceutical ingredients (APIs) and intermediates. The company sells its pharmaceuticals directly in the countries of its operations and through licensees in other places. Recordati is headquartered in Milan, Italy.
For a complete picture of Pasireotide’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
